Karolinska Institutet will use Advaxis immunotherapies to develop allergy treatments using the models that were developed at Karolinska.
Advaxis chairman/CEO Thomas Moore said: "The Karolinska Institutet is a world-renowned group of researchers and we are pleased that our immunotherapies may help to better understand allergic responses and potentially provide additional prevention and treatment options."